OMA1 Antibody

What is OMA1 and what is its primary function in cells?

OMA1 is a mitochondrial zinc metalloprotease that plays a crucial role in regulating mitochondrial dynamics and quality control. Its primary function involves the proteolytic processing of OPA1 (optic atrophy 1), a dynamin-like GTPase essential for mitochondrial fusion. Upon oxidative stress, OMA1 becomes activated and cleaves the long isoform of OPA1 (L-OPA1) at the S1 site, generating short OPA1 isoforms (S-OPA1) that promote mitochondrial fission . This cleavage occurs specifically between Arginine 194 and Alanine 195 residues of OPA1 . Additionally, OMA1 is part of the mitochondrial contact site and crista organizing system (MICOS) complex that regulates crista structure .

How does OMA1 activation affect mitochondrial homeostasis?

OMA1 activation serves as a stress-response mechanism that triggers mitochondrial fission through OPA1 cleavage. Under normal conditions, a balance between fusion and fission processes maintains mitochondrial network integrity. When cells experience stress (such as membrane depolarization or oxidative damage), OMA1 becomes activated and cleaves L-OPA1, shifting the balance toward fission. Recent research has shown that mutation of specific redox-sensing sites in OMA1 (particularly cysteine 403) impairs mitochondrial responses to stress, including ATP production, mitochondrial fission, and apoptotic sensitivity . These findings indicate that OMA1 plays a vital role in mitochondrial stress response and quality control mechanisms by facilitating the removal of damaged mitochondria through fission.

What is the relevance of OMA1-OPA1 axis in disease contexts?

The OMA1-OPA1 axis has significant implications in several disease contexts, particularly in cancer biology. In sarcoma models, mutation affecting OMA1 function (specifically the C403A mutation) has been shown to prevent tumor development in immunocompetent mice but not in immunodeficient models, suggesting a connection to anti-tumor immunity . In human soft tissue sarcomas, variations in OMA1 and OPA1 transcript levels have clinical significance—high OPA1 expression in primary tumors correlates with shorter metastasis-free survival after surgery, while low OPA1 expression associates with anti-tumor immune signatures .

In glioblastoma (GBM), OMA1 has been found to induce immune evasion through regulation of PD-1 binding and PD-L1 mediated T cell cytotoxicity . Specifically, OMA1 competitively binds to HSPA9 to promote mitophagy and mediates immune escape in GBM. This interaction activates the cGAS-STING pathway by increasing mitochondrial DNA release, which ultimately upregulates PD-L1 transcription .

What criteria should be considered when selecting an OMA1 antibody for research?

When selecting an OMA1 antibody for research applications, consider these critical factors:

• Target specificity: Verify the antibody recognizes human, mouse, or rat OMA1 based on your experimental model. Sequence alignments and cross-reactivity data should be reviewed.

• Application suitability: Confirm validation for your specific application (Western blot, IHC, IF, etc.). According to available data, validated OMA1 antibodies have been tested in:

  Application	Validated Cell Lines/Tissues	Recommended Dilution
  Western Blot	HeLa, HEK-293T, K-562, HepG2, SKOV-3, MDA-MB-231	1:1000-1:4000
  Immunohistochemistry	Human liver tissue	1:250-1:1000

• Clone type: Determine if monoclonal or polyclonal antibodies are more suitable for your application. Monoclonals offer higher specificity but might recognize a single epitope, while polyclonals provide broader recognition but potential cross-reactivity.

• Validation methods: Review literature demonstrating antibody specificity through knockout/knockdown controls or immunoprecipitation followed by mass spectrometry .

• Epitope information: Consider the antibody's target region, as OMA1 contains functional domains including the zinc-binding motif and transmembrane domains that might be masked in certain experimental conditions.

How can I validate an OMA1 antibody for my specific experimental system?

Validation of an OMA1 antibody in your specific experimental system should follow these methodological steps:

• Positive and negative controls: Use cell lines known to express OMA1 (such as HeLa, HEK-293T) as positive controls . For negative controls, use OMA1 knockout or knockdown models.

• Multiple detection methods: Cross-validate using complementary techniques (e.g., if using Western blot, confirm with immunofluorescence).

• Molecular weight verification: Confirm that the detected band matches the expected molecular weight of OMA1 (approximately 40-45 kDa for the mature form).

• Stress response testing: Since OMA1 is activated under mitochondrial stress, treat cells with CCCP (a protonophore that dissipates mitochondrial membrane potential) and verify increased OMA1 activation through OPA1 processing (increased S-OPA1/L-OPA1 ratio) .

• Specificity testing: Pre-absorb the antibody with recombinant OMA1 protein to confirm signal elimination.

• Functional correlation: Validate the antibody's ability to detect functional changes in OMA1 activity using the fluorescence-based reporter assay described by Tobacyk et al., which measures OMA1 enzymatic activity directly .

What is the most reliable method to measure OMA1 activity in experimental samples?

The most reliable method to measure OMA1 activity is a fluorescence-based reporter assay developed by Tobacyk et al. . This assay directly measures enzymatic activity rather than relying on protein levels, which may not reflect activation state.

The assay methodology involves:

• Using a fluorogenic peptide substrate derived from the OMA1-specific cleavage site in OPA1: MCA-AFRATDHG-(lys)DNP, which contains an MCA fluorophore on the N-terminus and a DNP quencher on the C-terminus.

• Upon cleavage by active OMA1 (specifically between Arginine and Alanine), the fluorophore separates from the quencher, resulting in measurable fluorescence.

• Protocol setup requires:

  • OMA1 activity assay buffer (50mM Tris/HCl, pH 7.5, 40mM KCl)

  • Protein sample (5 μg)

  • Optional: 200 μM TPEN (zinc chelator, added to inhibit OMA1 and confirm specificity)

  • OPA1 fluorogenic reporter substrate (5 μM final concentration)

• Activity is measured in a fluorescence plate reader with excitation at 320 nm and emission at 405 nm.

This method has been validated across multiple species, including rat, mouse, and human samples . The assay exhibits high sensitivity and can detect basal OMA1 activity in diverse cell types and tissues.

How can I induce and monitor OMA1 activation in cell culture systems?

OMA1 activation can be induced and monitored using the following experimental approaches:

• Induction methods:

  • Treatment with CCCP (10-20 μM, 1-4 hours): Depolarizes mitochondrial membrane potential

  • Hydrogen peroxide (100-500 μM, 1-2 hours): Induces oxidative stress

  • Oligomycin (5-10 μM): Inhibits ATP synthase

  • Antimycin A (10 μM): Blocks complex III of the electron transport chain

• Monitoring approaches:

  • OPA1 processing: The most established readout for OMA1 activation is monitoring OPA1 cleavage by Western blot. Upon activation, OMA1 cleaves L-OPA1 to increase the proportion of S-OPA1 .

  • Direct activity measurement: Using the fluorescence-based reporter assay described in question 3.1 .

  • Mitochondrial morphology: Visualization of mitochondrial network fragmentation using fluorescent markers like MitoTracker or immunofluorescence for mitochondrial proteins.

  • Protein complexes analysis: Blue-native gel electrophoresis (BNGE) to assess OPA1 incorporation into MICOS complexes before and after stress induction .

• Confirmation of specificity:

  • Use OMA1 knockout or knockdown cells as negative controls

  • Compare with zinc chelation (TPEN treatment), which inhibits OMA1 metalloprotease activity

  • Verify that a peptide lacking the RA cleavage sequence shows no processing

What are the key considerations when designing experiments to investigate OMA1-OPA1 interactions?

When designing experiments to investigate OMA1-OPA1 interactions, researchers should consider these critical factors:

• Baseline mitochondrial status assessment:

  • Mitochondrial membrane potential (using JC-1 or TMRM dyes)

  • Respiratory complex activity and supercomplex formation (through BNGE)

  • Basal levels of OPA1 isoforms (L-OPA1 vs. S-OPA1 ratio)

• Mutagenesis approaches:

  • Target specific residues known to affect OMA1 function, such as the redox-sensing cysteine 403, which can be mutated to alanine using prime editing or CRISPR-Cas9

  • Create cleavage-resistant OPA1 variants by mutating the S1 cleavage site (R194-A195)

• Compartment-specific analyses:

  • Mitochondrial subfractionation to separate inner membrane, outer membrane, and matrix components

  • Assessment of OMA1 integration into the MICOS complex through co-immunoprecipitation or proximity labeling approaches

• Functional readouts:

  • ATP production capacity following stress induction

  • Mitochondrial DNA release (relevant for immune activation)

  • Apoptotic sensitivity

  • Mitochondrial morphology dynamics using live-cell imaging

• Biochemical verification:

  • In vitro reconstitution using recombinant OMA1 proteins (containing the catalytic domain coupled to stabilizing partners like DsbC)

  • Artificial substrates based on OPA1 peptides containing the OMA1-specific cleavage site

• Controls for specificity:

  • Use peptides with mutated cleavage sites

  • Include OMA1-knockout models

  • Compare with other mitochondrial proteases (like YMEL1) that also process OPA1 but at different sites (S2/S3)

How does OMA1 contribute to cancer immunology and potential therapeutic approaches?

OMA1 has emerged as a significant factor in cancer immunology through several mechanisms:

• Mitochondrial stress signaling: Mutation of OMA1 (specifically C403A) prevents tumor development in immunocompetent mice but not in immunodeficient models, suggesting that OMA1 inactivation enhances anti-tumor immunity . This is mediated through:

  • Increased mitochondrial DNA release when OMA1 function is impaired

  • Enhanced priming of CD8+ lymphocytes that accumulate in OMA1-mutant tumors

• Immune checkpoint regulation in GBM: OMA1 has been shown to promote immune evasion in glioblastoma through:

  • Competitive binding to HSPA9 to induce mitophagy

  • Promotion of PD-L1 expression through activation of the cGAS-STING pathway

  • Regulation of PD-1 binding and PD-L1 mediated T-cell cytotoxicity

• Prognostic implications: In soft tissue sarcomas, the expression levels of OMA1 and OPA1 correlate with clinical outcomes and immune signatures:

  • High OPA1 expression associates with shorter metastasis-free survival

  • Low OPA1 expression correlates with anti-tumor immune signatures

Potential therapeutic approaches leveraging OMA1 biology include:

• Targeted inhibition: Developing specific OMA1 inhibitors to enhance tumor immunogenicity, particularly in sarcomas and glioblastomas.

• Combination therapies: Pairing OMA1 inhibition with immune checkpoint blockade (anti-PD-1/PD-L1) to potentially overcome resistance to immunotherapy.

• Biomarker development: Using OMA1/OPA1 expression or activation states as predictive biomarkers for immunotherapy response.

• Synthetic lethality approaches: Targeting OMA1 in combination with agents that further stress mitochondrial function in cancer cells.

What is the relationship between OMA1 redox sensing and mitochondrial quality control mechanisms?

The relationship between OMA1 redox sensing and mitochondrial quality control involves sophisticated molecular mechanisms:

The importance of this redox-sensing mechanism is highlighted by the finding that mutation of Cysteine 403 to Alanine disrupts this regulatory system, with significant consequences for mitochondrial function, stress response, and even tumor immune surveillance .

How do respiratory complex assembly defects relate to OMA1 function in different tissues?

The relationship between OMA1 function and respiratory complex assembly varies between tissues and exhibits complex interactions:

• Tissue-specific effects of OMA1 deficiency:

  • In liver-specific OPA1 knockout (OPA1 LKO) models, proteomic analyses revealed significant alterations in respiratory complex composition :

    • Decreases in multiple subunits of complexes I and IV

    • Increases in subsets of complexes II and V subunits

    • Elevated cytochrome c levels

    • Compensatory increases in assembly factors for complexes I and IV

• Supercomplex assembly disruption:

  • Blue-native gel electrophoresis (BNGE) demonstrated that OPA1 knockout significantly decreased levels of supercomplexes [I+III₂] and [I+III₂+IV]

  • Complex II levels increased, possibly to support anaplerotic reactions through the TCA cycle

  • Complex IV and complex IV-containing supercomplexes showed significant decreases with accumulation of a complex IV subassembly

• Mtochondrial DNA content versus OMA1 function:

  • The complex V assembly defect in OPA1-knockout liver appears to be a specific effect of OPA1 deletion rather than a general consequence of decreased mtDNA levels

  • This is supported by comparison with Mfn-DKO MEFs, which show different patterns of complex assembly despite mtDNA depletion

  • OPA1 depletion causes more severe respiratory defects than Mfn-DKO in MEFs, indicating a poor correlation between mitochondrial function and mtDNA levels

• Integrated stress response activation:

  • In liver tissue, OPA1 knockout induces an efficient integrated stress response (ISR)

  • This increases mitochondrial biogenesis (including mtDNA) to preserve mitochondrial function

  • Despite this compensation, the pronounced complex V assembly defect suggests a specific role for OPA1 in complex V assembly or stability

These findings highlight that OMA1-OPA1 interactions influence respiratory complex assembly beyond their known roles in mitochondrial dynamics, with tissue-specific consequences that may reflect different metabolic demands and stress response capabilities.

What are common challenges in detecting OMA1 activity and how can they be addressed?

Researchers face several challenges when detecting OMA1 activity due to its regulated activation and rapid turnover. Here are the common issues and solutions:

• Low basal activity levels:

  • Challenge: OMA1 exhibits low activity under basal conditions, making detection difficult.

  • Solution: Use the fluorescence-based reporter assay with optimized sensitivity . Extend measurement time to capture small changes in fluorescence. Include positive controls like CCCP-treated samples to validate assay functionality.

• Specificity concerns:

  • Challenge: The fluorogenic peptide substrate may be cleaved by other proteases.

  • Solution: Use TPEN (zinc chelator) to inhibit OMA1 activity as a specificity control . Include OMA1 knockout/knockdown samples as negative controls. Verify specificity using peptides with mutated cleavage sites that should not be processed.

• Transient activation:

  • Challenge: OMA1 activation can be rapid and transient, making timing critical.

  • Solution: Perform time-course experiments after stress induction (e.g., CCCP treatment) to identify optimal detection windows. Use OPA1 processing as a parallel readout for verification.

• Sample preparation issues:

  • Challenge: Mitochondrial membrane proteins like OMA1 can be difficult to solubilize while maintaining native conformation and activity.

  • Solution: Optimize lysis conditions using mild detergents (0.5-1% digitonin or 0.5% DDM) for activity assays. Maintain samples at 4°C throughout preparation to preserve enzyme activity.

• Inter-assay variability:

  • Challenge: Variability between experiments can complicate interpretation.

  • Solution: Normalize OMA1 activity to total protein concentration. Include internal standards across experiments. Report fold changes relative to untreated controls rather than absolute values.

• Reagent stability:

  • Challenge: Fluorogenic peptide substrates may degrade over time.

  • Solution: Prepare fresh working dilutions for each experiment. Store stock solutions in small aliquots at -80°C. Test substrate functionality regularly with positive controls.

How can I distinguish between OMA1-dependent and OMA1-independent effects on mitochondrial function?

Distinguishing between OMA1-dependent and OMA1-independent effects on mitochondrial function requires careful experimental design:

• Genetic approaches:

  • CRISPR-Cas9 OMA1 knockout: Generate complete OMA1 knockout models to establish baseline OMA1-independent functions.

  • Point mutations: Create specific mutations (e.g., C403A) that affect OMA1 activation while preserving protein presence, helping separate structural from catalytic roles.

  • Rescue experiments: Reintroduce wild-type or mutant OMA1 into knockout models to confirm phenotype specificity.

• Biochemical discrimination:

  • Substrate specificity: Monitor processing of OMA1-specific substrates (OPA1 S1 site cleavage) versus substrates processed by other proteases (e.g., YMEL1-mediated OPA1 cleavage at S2/S3 sites) .

  • Inhibitor profiles: Use zinc chelators like TPEN that inhibit OMA1 metalloprotease activity but verify effects on other metalloproteases .

  • Activity assays: Apply the fluorescence-based OMA1 activity assay with appropriate controls to directly measure enzymatic activity .

• Temporal resolution:

  • Acute vs. chronic effects: Compare short-term stress responses (where OMA1 activation predominates) with long-term adaptations (where compensatory mechanisms emerge).

  • Inducible systems: Use inducible OMA1 knockout/knockdown systems to distinguish immediate consequences from adaptive responses.

• Pathway dissection:

  • Epistasis experiments: Determine whether phenotypes persist when downstream effectors are manipulated (e.g., expressing non-cleavable OPA1 in OMA1-active backgrounds).

  • Parallel pathway inhibition: Inhibit alternative stress response pathways (e.g., PINK1/Parkin-mediated mitophagy) to isolate OMA1-specific contributions.

• Functional readouts:

  • OPA1 cleavage pattern analysis: Distinguish between stress-induced OMA1-mediated (S1 site) and constitutive YMEL1-mediated (S2/S3 sites) OPA1 processing .

  • Mitochondrial morphology quantification: Differentiate between fission induced by OMA1 activation versus DRP1-mediated fission independent of OMA1.

  • Specific downstream consequences: Measure mitochondrial DNA release, which appears to be specifically enhanced in OMA1 C403A mutants .

What considerations are important when using OMA1 antibodies for studying protein-protein interactions?

When using OMA1 antibodies to study protein-protein interactions, researchers should address these critical considerations:

• Epitope accessibility in complexes:

  • Challenge: OMA1 interactions with partners like HSPA9 or components of the MICOS complex may mask antibody epitopes.

  • Solution: Use multiple antibodies targeting different regions of OMA1. Test antibodies in native vs. denaturing conditions to identify those suitable for detecting OMA1 in complexes.

• Validation of interactions:

  • Challenge: Distinguishing specific from non-specific interactions.

  • Solution: Perform reciprocal co-immunoprecipitations. Validate with alternative methods (proximity ligation assay, FRET, split-GFP systems). Include appropriate negative controls (IgG, knockout samples).

• Preserving native interactions:

  • Challenge: Harsh lysis conditions may disrupt physiologically relevant interactions.

  • Solution: Use mild detergents (digitonin 0.5-1%, NP-40 0.1-0.5%) for co-IP. Consider crosslinking approaches for transient interactions. Optimize buffer conditions (salt concentration, pH) based on predicted interaction characteristics.

• Activation state considerations:

  • Challenge: OMA1 interactions may be dependent on its activation state.

  • Solution: Compare interaction profiles under basal and stress conditions (e.g., CCCP treatment). Use catalytically inactive OMA1 mutants to distinguish structural from activity-dependent interactions.

• Subcellular localization:

  • Challenge: Ensuring detection of interactions in the correct cellular compartment.

  • Solution: Perform fractionation to isolate mitochondria before immunoprecipitation. Use immunofluorescence microscopy to verify colocalization prior to biochemical analysis.

• Post-translational modifications:

  • Challenge: Modifications may affect interaction affinity and antibody recognition.

  • Solution: Use phosphatase/deubiquitinase inhibitors during sample preparation if modifications are suspected to be important. Consider using modification-specific antibodies if relevant post-translational modifications are known.

• Technical approach selection:

  • For stable interactions: Conventional co-IP followed by Western blotting

  • For transient interactions: Crosslinking prior to immunoprecipitation

  • For comprehensive interactome analysis: Immunoprecipitation followed by mass spectrometry, as performed in GBM studies identifying OMA1-HSPA9 interactions

  • For mapping interaction domains: Pull-down assays with recombinant protein fragments

How might targeting OMA1 activity contribute to novel immunotherapeutic approaches?

Targeting OMA1 activity presents several promising avenues for novel immunotherapeutic approaches based on its emerging roles in immune regulation:

• Enhancing immunotherapy responsiveness:

  • Research has shown that OMA1 inactivation (specifically the C403A mutation) prevents tumor development in immunocompetent mice through enhanced anti-tumor immunity .

  • Pharmacological inhibition of OMA1 could potentially:

    • Increase mitochondrial DNA release, stimulating the cGAS-STING pathway

    • Enhance CD8+ T cell priming and tumor infiltration

    • Overcome resistance to existing immunotherapies

• Checkpoint inhibitor synergy:

  • OMA1 has been found to induce immune evasion in glioblastoma through regulation of PD-1 binding and PD-L1-mediated T cell cytotoxicity .

  • Targeting the OMA1/HSPA9/cGAS/PD-L1 axis could:

    • Reduce checkpoint inhibitor expression in tumors

    • Complement existing anti-PD-1/PD-L1 therapies

    • Provide benefit in traditionally immunotherapy-resistant cancers like GBM

• Biomarker development:

  • OMA1 and OPA1 expression levels correlate with immune signatures and clinical outcomes in soft tissue sarcomas .

  • This could enable:

    • Stratification of patients for immunotherapy based on OMA1/OPA1 expression

    • Development of companion diagnostics for immunotherapy selection

    • Monitoring of treatment efficacy through changes in OMA1 activity

• Combination therapy approaches:

  • Pairing OMA1 inhibitors with:

    • Conventional immunotherapies (checkpoint inhibitors)

    • Mitochondrial-targeting drugs that further enhance mitochondrial DNA release

    • STING agonists to amplify downstream immune signaling

• Delivery systems development:

  • Cancer-specific delivery of OMA1 inhibitors using:

    • Nanoparticle delivery systems targeting tumor microenvironment

    • Cell-penetrating peptides with tumor-homing capabilities

    • Mitochondria-targeted delivery vehicles to enhance specificity

Methodological considerations for translating these approaches include:

• High-throughput screening for small molecule OMA1 inhibitors using the fluorescence-based reporter assay

• In vivo validation using syngeneic mouse models with intact immune systems

• Combination therapy testing to identify optimal sequencing and dosing

• Assessment of immune infiltrate changes in response to OMA1 modulation

What role does the OMA1 redox sensing mechanism play in neurodegenerative diseases?

While the search results don't directly address OMA1's role in neurodegenerative diseases, we can extrapolate from the established functions of OMA1 and the known importance of mitochondrial dynamics in neurodegeneration:

• Potential relevance to neurodegenerative mechanisms:

  • Mitochondrial dysfunction is a hallmark of many neurodegenerative diseases including Alzheimer's, Parkinson's, and Huntington's diseases.

  • OMA1's redox-sensing function through cysteine 403 could be critical in neurons, which:

    • Have high energy demands making them vulnerable to mitochondrial dysfunction

    • Experience increased oxidative stress during neurodegeneration

    • Require efficient mitochondrial quality control due to their post-mitotic nature

• OPA1 processing implications:

  • OPA1 is essential for maintaining mitochondrial cristae structure and respiratory efficiency.

  • Excessive OMA1 activation in response to oxidative stress could lead to:

    • Increased OPA1 cleavage and mitochondrial fragmentation

    • Disruption of respiratory supercomplex organization

    • Compromised ATP production in neurons

    • Enhanced cytochrome c release and neuronal apoptosis

• Mitochondrial quality control failures:

  • Dysregulated OMA1 redox sensing might impair mitochondrial quality control by:

    • Causing inappropriate fission/fusion balance

    • Altering mitophagy efficiency

    • Leading to accumulation of damaged mitochondria in neuronal processes

    • Compromising mitochondrial transport along axons

• Experimental approaches to investigate:

  • Generate neuronal models with OMA1 C403A mutation to assess:

    • Mitochondrial morphology and transport in neurites

    • Neuronal vulnerability to oxidative stressors

    • Synaptic function and maintenance

    • Protection against neurotoxic insults

• Therapeutic implications:

  • Modulating OMA1 activity could potentially:

    • Preserve mitochondrial function during oxidative stress

    • Protect against excessive mitochondrial fragmentation

    • Maintain respiratory efficiency through preserved cristae structure

    • Prevent neurodegenerative progression

Given that OMA1 redox sensing represents a critical link between oxidative stress and mitochondrial dynamics, further research specifically targeting neuronal models is warranted to fully elucidate its role in neurodegenerative pathology.